FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 20925 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76 K trial. PMID 40139004 · Eur J Cancer · 2025-May-02 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Induction chemotherapy followed by chemoradiation in locally advanced cervical cancer: Quality of life outcomes of the GCIG INTERLACE trial. PMID 40139003 · Eur J Cancer · 2025-May-02 The report is a quality-of-life analysis of a Phase III randomized trial in oncology. While it meets criteria for oncology, human, randomized, phase 3, drug intervention, and original result, it does not have a primary or key secondary time-to-event efficacy endpoint as required. The endpoint is quality of life, which is excluded per adjudication rules. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Radiation vs. trans-oral surgery for treatment de-escalation in HPV-related oropharyngeal cancers: Primary analysis of the ORATOR2 randomized trial. PMID 40121836 · Eur J Cancer · 2025-May-02 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Adjuvant chemotherapy compared to observation in resected biliary tract cancers: Survival meta-analysis of phase-III randomized controlled trials. PMID 40101432 · Eur J Cancer · 2025-May-02 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2024. PMID 40058879 · Eur Heart J Cardiovasc Pharmacother · 2025-May-02 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| The Effect of Surgeon Experience on the Recurrence of Non-Muscle Invasive Bladder Cancer (NMIBC), Following Transurethral Resection of the Bladder Tumor (TURBT): A double Blinded Prospective Randomized Study. PMID 40439390 · Asian Pac J Cancer Prev · 2025-May-01 Study is a randomized trial on surgical technique in oncology, but lacks a drug intervention and a time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effect of Structured Exercise-based rehabilitation on Sarcopenia and Quality of life among Head and Neck Cancer Patients Undergoing Chemo-radiotherapy: A Randomized Controlled Trial. PMID 40439377 · Asian Pac J Cancer Prev · 2025-May-01 The study is an oncology RCT in humans with a primary result, but it is not eligible because it does not involve a drug-containing intervention (exercise is non-drug), does not report a time-to-event efficacy endpoint (outcomes are changes in sarcopenia and QOL scores), and the phase (III/IIIb or II/III) is not established. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Evaluating the Test-Negative Design for COVID-19 Vaccine Effectiveness Using Randomized Trial Data: A Secondary Cross-Protocol Analysis of 5 Randomized Clinical Trials. PMID 40434773 · JAMA Netw Open · 2025-May-01 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Tocilizumab Monotherapy or Combined With Methotrexate for Rheumatoid Arthritis: A Randomized Clinical Trial. PMID 40388166 · JAMA Netw Open · 2025-May-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Becoming attack-free further improves health-related quality of life in patients with hereditary angioedema receiving garadacimab. PMID 40380356 · Allergy Asthma Proc · 2025-May-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Combining Exercise Training and Testosterone Therapy in Older Women After Hip Fracture: The STEP-HI Randomized Clinical Trial. PMID 40372752 · JAMA Netw Open · 2025-May-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Enzalutamide and Prostate-Specific Antigen Levels in Metastatic Prostate Cancer: A Secondary Analysis of the ARCHES Randomized Clinical Trial. PMID 40332939 · JAMA Netw Open · 2025-May-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Randomized-Controlled Trial Comparing Safety and Efficacy of Repairing Balm vs Topical Antimicrobial for Post-Procedural Wounds. PMID 40327581 · J Drugs Dermatol · 2025-May-01 The study is a randomized trial on wound healing for actinic keratoses (pre-cancerous), not a Phase II/III or Phase III/IIIb trial of a drug-containing intervention for human malignant neoplasm with a time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| HLA DQA1*05 and Risk of Antitumor Necrosis Factor Treatment Failure and Anti-Drug Antibody Development in Children With Crohn's Disease. PMID 40315028 · Am J Gastroenterol · 2025-May-01 The study is a randomized trial with a time-to-event primary endpoint and drug intervention, but it focuses on Crohn's disease, which is not an oncology indication (human malignant neoplasm). Therefore, it is excluded from the oncology KM digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic Phenotype. PMID 40305712 · N Engl J Med · 2025-May-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis. PMID 40193122 · JAMA Neurol · 2025-May-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Prevalence and Medium-Term Outcomes of Patients with Biopsy-Proven Intermediate- to High-Risk Prostate Adenocarcinoma with Low Intraprostatic Uptake on [68Ga]Ga-PSMA-11 PET/CT in the proPSMA Study. PMID 40147846 · J Nucl Med · 2025-May-01 The study is a randomized controlled trial in oncology (prostate cancer) with a drug intervention, but it is not eligible because the primary outcome is not a time-to-event endpoint with reported KM/HR analysis, and the phase is not explicitly confirmed as Phase III. The report is a secondary subgroup analysis. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Immunotherapy Strategies After Immune Checkpoint Inhibitor Exposure in Renal Cell Carcinoma: A Review. PMID 40146173 · JAMA Oncol · 2025-May-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Cocoa Flavanol Supplementation and Risk of Age-Related Macular Degeneration: An Ancillary Study of the COSMOS Randomized Clinical Trial. PMID 40146119 · JAMA Ophthalmol · 2025-May-01 The study is a randomized trial of a dietary supplement for age-related macular degeneration, not a drug intervention for human malignant neoplasm. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Reldesemtiv in Amyotrophic Lateral Sclerosis: Results From the COURAGE-ALS Randomized Clinical Trial. PMID 40126464 · JAMA Neurol · 2025-May-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| A Randomized Clinical Trial of Prolonged Exposure Therapy With and Without Topiramate for Comorbid PTSD and Alcohol Use Disorder. PMID 40103353 · Am J Psychiatry · 2025-May-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Early Fasting Serum Glucose or Weight Reduction With Tirzepatide and Metabolic Outcomes in People With Type 2 Diabetes: A Post Hoc Analysis of the SURPASS Trials. PMID 40100982 · Diabetes Care · 2025-May-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Precision Exercise Effect on Fatigue and Function in Lung Cancer Surgery: A Randomized Clinical Trial. PMID 40072448 · JAMA Surg · 2025-May-01 The study is a randomized Phase 3 trial in lung cancer patients, but it evaluates an exercise intervention (non-drug) and uses functional/fatigue endpoints, not time-to-event efficacy endpoints required for this cohort. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease: Secondary Analysis of the TRAILBLAZER-ALZ and ALZ 2 Randomized Clinical Trials. PMID 40063015 · JAMA Neurol · 2025-May-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Efficacy, Safety, and Tolerability of Oral DFD-29, a Low-Dose Formulation of Minocycline, in Rosacea: Two Phase 3 Randomized Clinical Trials. PMID 40042869 · JAMA Dermatol · 2025-May-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Health-Related Quality of Life in Patients with HR+/HER2- Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial. PMID 40019493 · Clin Cancer Res · 2025-May-01 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | no_km 0 Figure · 0 Panel · risk not_applicable |
| 177Lu-DOTATATE in Combination with PARP Inhibitor Olaparib Is Feasible in Patients with Somatostatin-Positive Tumors: Results from the LuPARP Phase I Trial. PMID 40015919 · J Nucl Med · 2025-May-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant Paclitaxel/Olaparib in Comparison to Paclitaxel/Carboplatin in Patients with HER2-Negative Breast Cancer and HRD-Long-term Survival of the GeparOLA Study. PMID 39998850 · Clin Cancer Res · 2025-May-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Tight Control and Radiological Progression: The Radiographic Outcomes of the TICOPA Study. PMID 39892892 · J Rheumatol · 2025-May-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Effect of Bimekizumab on Patient-Reported Outcomes and Work Productivity in Patients With Psoriatic Arthritis: 1-Year Results From 2 Phase III Studies. PMID 39892885 · J Rheumatol · 2025-May-01 The record describes a Phase III randomized trial of bimekizumab in psoriatic arthritis, which is a non-oncologic inflammatory condition. The primary and secondary endpoints are patient-reported outcomes (pain, fatigue, function, quality of life) and work productivity, not time-to-event efficacy endpoints (e.g., OS, PFS, DFS) with Kaplan-Meier or HR analysis as required for this cohort. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Early Cold-stored Platelet Transfusion following Traumatic Brain Injury: A Randomized Clinical Trial. PMID 39840438 · Ann Surg · 2025-May-01 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Brief Report: Resolution of Neuropsychiatric Adverse Events After Switching to a Doravirine-Based Regimen in the Open-Label Extensions of the DRIVE-AHEAD and DRIVE-FORWARD Trials. PMID 39748155 · J Acquir Immune Defic Syndr · 2025-May-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| A Randomized Study of Consolidation Chemoradiotherapy Versus Observation After First-line Chemotherapy in Advanced Gallbladder Cancers: RACE-GB study. PMID 39675683 · Int J Radiat Oncol Biol Phys · 2025-May-01 The study is a randomized trial in advanced gallbladder cancer (oncology, human, malignant neoplasm) with a drug-containing intervention (capecitabine) and a primary time-to-event efficacy endpoint (OS). It is an original report of results. While the explicit phase is not stated in the metadata, the trial design (randomized comparison against observation as the standard of care) and the primary OS endpoint with significant results indicate a definitive (Phase III-level) randomized trial. All required criteria are explicitly established. |
B
|
影子组漏检补回 | eligiblemodel_adjudicated_eligible | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Justification, margin values, and analysis populations for oncologic noninferiority and equivalence trials: a meta-epidemiological study. PMID 39657246 · J Natl Cancer Inst · 2025-May-01 The record is a meta-epidemiological study analyzing the design and reporting of Phase III randomized oncology trials, not an original result report of a specific drug-containing trial. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial. PMID 39656951 · J Natl Cancer Inst · 2025-May-01 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Differential long-term tamoxifen therapy benefit by menopausal status in breast cancer patients: secondary analysis of a controlled randomized clinical trial. PMID 39656627 · J Natl Cancer Inst · 2025-May-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Association between Locoregional Failure and NFE2L2/KEAP1/CUL3 Mutations in NRG/RTOG 9512: A Randomized Trial of Radiation Fractionation in T2N0 Glottic Cancer. PMID 39656603 · Clin Cancer Res · 2025-May-01 The study is a secondary analysis of biomarker association within a Phase III randomized trial (NRG/RTOG 9512) of radiation fractionation. It meets criteria for oncology, human, randomized, phase 3, and time-to-event endpoints, but the intervention is radiation alone, not a drug-containing regimen. Therefore, it is excluded. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Multi-domain effectiveness of guselkumab evaluated via composite indices through 1 year in patients with PsA and inadequate response to TNFi: post hoc analysis of COSMOS. PMID 39437003 · Rheumatology (Oxford) · 2025-May-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
B
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| A phase 2 study of decitabine with or without carboplatin and arsenic trioxide in patients with MDS and AML. PMID 40453133 · Blood Neoplasia · 2025-May 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Prognostic impact of RDI of vincristine in patients with DLBCL receiving R-CHOP: a supplementary analysis of JCOG0601. PMID 40453132 · Blood Neoplasia · 2025-May 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | confirmed 3 Figure · 5 Panel · risk visible |
| Patient-reported outcomes with trastuzumab deruxtecan in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer: results from the randomized DESTINY-Breast06 trial. PMID 40441802 · ESMO Open · 2025-May The record is from the DESTINY-Breast06 Phase III randomized trial, which is oncology, human, randomized, and drug-intervening. However, this specific abstract and record focus exclusively on patient-reported outcome (PRO) endpoints and quality of life (QOL) deterioration, which are secondary or health-related outcomes, not the primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS) required for the cohort. The primary efficacy results (time-to-event) are mentioned as background but are not reported here. Therefore, it is excluded based on report type. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Intraoperative indocyanine green fluorescence angiography in colorectal surgery to prevent anastomotic leakage: A single-blind phase III multicentre randomized controlled trial (FLUOCOL-01/FRENCH 21/GRECCAR 19 intergroup trial). PMID 40415381 · Colorectal Dis · 2025-May This is a Phase III randomized controlled trial protocol for a diagnostic/procedural intervention (indocyanine green fluorescence angiography) in colorectal surgery. The primary endpoint is anastomotic leak (a complication), not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS). It does not meet the required drug intervention or time-to-event endpoint criteria, and it is a protocol without reported results. |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Cost-utility analysis of the DREAMS START intervention for people living with dementia and their carers: a within-trial economic evaluation. PMID 40412418 · Lancet Healthy Longev · 2025-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Impact of Providing an Automated Telephone Option to Report Weekly Patient-Reported Outcome Measures in the PRO-TECT Trial (AFT-39) on Disparity Gaps in Symptom Management and Outcomes. PMID 40408610 · JCO Clin Cancer Inform · 2025-May The study is a randomized oncology trial with original results, but it does not involve a drug-containing intervention (it tests a PROM reporting system) and does not have a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS) as a main focus, with only survival mentioned as an exploratory outcome at 12 months without detailed KM or HR results. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Health-related quality of life with daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible patients with newly diagnosed multiple myeloma: analysis of the phase 3 OCTANS study. PMID 40407887 · Ann Hematol · 2025-May 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | no_km 0 Figure · 0 Panel · risk not_applicable |
| A Novel Fixed Dose Triple Combination Therapy (IDP-126) for Moderate to Severe Acne. PMID 40403331 · Skin Therapy Lett · 2025-May 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Low-Dose Anti-PD1 Immune Checkpoint Inhibitors in Relapsed/Refractory Hodgkin Lymphoma: A Systematic Review. PMID 40403200 · JCO Glob Oncol · 2025-May 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Triple Oral Metronomic Chemotherapy Versus Chemotherapy of Physician Discretion After Failure of Platinum-Based Therapy in Advanced Head and Neck Cancer: A Phase III Randomized Study (METRO-CHASE Study). PMID 40403198 · JCO Glob Oncol · 2025-May 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Impact of High-Titer Convalescent Plasma on Clinical and Virologic Outcomes Among Veterans Hospitalized With SARS-CoV-2 Infection: VA CoronavirUs Research and Efficacy Studies-1 (VA CURES-1). PMID 40400480 · J Med Virol · 2025-May 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Health-related quality of life in patients with aggressive non-Hodgkin lymphoma: results from the PETAL trial. PMID 40397196 · Ann Hematol · 2025-May The record is a quality-of-life analysis from a Phase III randomized trial with a drug intervention. While it meets criteria for oncology, human, randomized, phase, drug intervention, and original result, it is excluded because the report's primary focus and presented endpoint is not a time-to-event efficacy endpoint. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |